Biostatistics Consulting | Clinical Trials

☎ (412) 860-3113☎ (412) 860-3113 Contact@ConfluenceStat.comContact@ConfluenceStat.com

ConfluenceStat, LLC, was founded by Jason Connor, PhD, a uniquely trained and experienced clinical trialist and statistician.

We offer biostatistical consulting focusing on clinical trials, Bayesian statistics, and strategic statistical communication for regulatory designs and filings. Our experience includes all clinical trials, though we specialize in innovative trials, including Bayesian, adaptive, and platform trials. We have a rich experience in drug, biological, and device trials, including orphan and rare diseases, and over a decade of experience working with clients in discussions with the U.S. Food and Drug Administration (FDA).

Additionally, we provide TrialDX^SM, a service to independently evaluate clinical trials for sponsors or investors. We also provide expertise for sponsors seeking an experienced data monitoring committee (DMC) statistician.

Clinical trials require extensive collaboration and communication. A clinical trial statistician who understands the clinical situation and effectively communicates with investigators, sponsors, regulators, patients, patient advocates, and other key stakeholders is vital to the success of a clinical trial.

Column

At ConfluenceStat, LLC, we believe innovation happens at the crossroads and, therefore, provide not only statistical consulting but also coordinate with your clinical, regulatory, and statistical teams to create clear, concise, and strategic designs, plans, statistical graphics, documents, and presentations. Our services extend throughout the process, from clinical trial designs through FDA submission and approval.

The name ConfluenceStat signifies the importance of having an experienced clinical trial statistician at the intersection, or confluence, of your executive, clinical and regulatory teams throughout drug or device development. It also reflects our founder’s unique background in biomedical engineering, statistics, and public policy and how that combination of experiences converges to provide insight into your drug or device development and to produce a successful, reliable, interpretable clinical trial.